What is Cerus Corporation (CERS)?

Cerus Corporation (CERS) is a stock in the Healthcare sector, Medical - Devices industry. View full analysis on Stocks360.

What is the current price of CERS?

The current price of CERS is $2.42. Prices are updated in real time on Stocks360.

What is CERS's price-to-earnings (PE) ratio?

CERS's trailing twelve-month PE ratio is -66.85, based on current price and earnings per share data available on Stocks360.

What is CERS's market capitalization?

CERS's market capitalization is $487,690,253.00, placing it in the small-cap tier.

Cerus Corporation (CERS)

Stock analysis · NASDAQ · Healthcare · Medical - Devices

$2.42

Market Cap

$487.69M

PE (TTM)

-66.85

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.83

Day Range

$2.40 – $2.49

52-wk Range

$1.38 – $3.47

Avg Volume

N/A

Volume

1.46M

Cerus Corporation (CERS) is a publicly traded company in the Healthcare sector. Latest price: $2.42. Market cap $487.69M. Trailing PE -66.85. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $1.45 2026-10-28 · $2.42 (+66.90%)

Earnings

Most Recent

Jul 30, 2026

EPS $-0.01 vs est. $-0.01

Beat by $0.00

Next Earnings

Nov 2, 2026

EPS estimate $-0.01

Proprietary Signals

Signal snapshot temporarily unavailable.

About Cerus Corporation

Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Establish…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-66.85×
P/S (TTM)	2.20×
P/B	6.93×
P/FCF (TTM)	-266.64×
EV / EBITDA	187.93×
EV / Sales	2.47×
Earnings Yield	-1.40%
Free Cash Flow Yield	-0.38%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$546.51M
Revenue (TTM)	$221.55M
Net Income (TTM)	-$6.82M
Free Cash Flow (TTM)	$7.20M
Net Debt	$58.82M
Working Capital	$71.52M
Gross Margin	52.05%
Operating Margin	-0.73%
Net Margin	-3.06%
Return on Equity	-10.31%
Return on Invested Capital	-1.06%